EyePoint Pharmaceuticals Investor Relations Material

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company's clinical development pipeline includes vosoritide for the treatment of glaucoma; Zimura for dry eye; and NeoChill for the reduction of intraocular pressure. It also conducts research and development activities for new products that address diseases primarily affecting the eye. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.